8-K Announcements
2Material company update
Feb 27, 2026·SEC
Material company update
Feb 26, 2026·SEC
Atrium Therapeutics, Inc.(RNA)Earnings, Financials & Key Ratios
RNA•NASDAQ
$13.19
Price updated Jun 27, 2026
AboutAvidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Show more
- Revenue$19M+70.9%
- EBITDA-$76M+79.7%
- Net Income-$77M+76.2%
- EPS (Diluted)-4.48-55.0%
- Gross Margin100%
- EBITDA Margin-410.84%+88.1%
- Operating Margin-412.58%+88.1%
- Net Margin-411.88%+86.1%
- ROE-9.4%+71.9%
RNA Price & Volume
Atrium Therapeutics, Inc. (RNA) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Milestone Revenue Growth
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial execution failure
"Atrium Therapeutics remains a high-risk, pre-commercial entity where the potential of its AOC platform is currently overshadowed by extreme cash burn and erratic, milestone-dependent revenue. The company's reliance on external financing to sustain its $154.9M quarterly R&D expenditure creates significant long-term dilution risk for shareholders. Investors should monitor the firm's ability to manage anti-drug antibody risks and stabilize its $234.1M equity base before considering a position."
Verdict Logic
the company's reliance on non-recurring milestone revenue and the massive $19.0M quarterly stock-based compensation expense in 2025Q3 suggest an unsustainable financial trajectory for long-term investors.
RNA Growth Metrics
Atrium Therapeutics, Inc. (RNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years22.36%
3 Years26.38%
TTM312.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-7.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-71.1%
Return on Capital
10 Years-31.36%
5 Years-31.49%
3 Years-29.39%
Last Year-9.02%
RNA Recent Earnings
Atrium Therapeutics, Inc. (RNA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 14, 2026Metric
Actual
Est
EPS
$0.97+7.6%
$1.05
Rev
$20M+881.8%
$2M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$1.70-37.1%
$1.24
Rev
$859,000-59.4%
$2M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.61+50.8%
$1.24
Rev
$2M+6.0%
$2M
Q1 2026
Feb 23, 2026Metric
Actual
Est
EPS
$1.59-20.5%
$1.32
Rev
$860,000-56.6%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.97vs $1.05+7.6% | $20Mvs $2M+881.8% |
| Q2 2026 | Mar 2, 2026 | $1.70vs $1.24-37.1% | $859,000vs $2M-59.4% |
| Q1 2026 | Feb 26, 2026 | $0.61vs $1.24+50.8% | $2Mvs $2M+6.0% |
| Q1 2026 | Feb 23, 2026 | $1.59vs $1.32-20.5% | $860,000vs $2M-56.6% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Atrium Therapeutics, Inc. (RNA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.19 | $225.62M | -2.94 | 70.85% | -411.88% | -9.4% | — | |
| $16.85 | $1.78B | -2.36 | 15.58% | 2.98% | 4.89% | — | |
| $15.19 | $165M | -7.23 | -16.14% | -180.3% | -67.22% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $30.77 | $3.03B | -5.28 | 20.13% | -91.03% | — | — | |
| $59.00 | $11.35B | 32.78 | 12.87% | 8.29% | 4.41% | — |
Compare RNA vs Peers
Atrium Therapeutics, Inc. (RNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RNA SEC Filings & Documents
Atrium Therapeutics, Inc. (RNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when RNA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RNA Frequently Asked Questions
Atrium Therapeutics, Inc. (RNA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Atrium Therapeutics, Inc.'s revenue?
Atrium Therapeutics, Inc. (RNA) reported $36.8M in revenue for fiscal year 2025. This represents a 9614% increase from $0.4M in 2018.
How fast is Atrium Therapeutics, Inc. growing?
Atrium Therapeutics, Inc. (RNA) grew revenue by 70.9% over the past year. This is strong growth.
Is RNA profitable?
Atrium Therapeutics, Inc. (RNA) reported a net loss of $396.5M for fiscal year 2025.
Dividend & Returns
What is RNA's return on equity?
Atrium Therapeutics, Inc. (RNA) has a return on equity (ROE) of -9.4%. Negative ROE indicates the company is unprofitable.
What is Atrium Therapeutics, Inc.'s free cash flow?
Atrium Therapeutics, Inc. (RNA) had negative free cash flow of $416.4M in fiscal year 2025, likely due to heavy capital investments.